MX340446B - Metodos para tratar y prevenir infecciones por estafilococo dorado y condiciones asociadas. - Google Patents

Metodos para tratar y prevenir infecciones por estafilococo dorado y condiciones asociadas.

Info

Publication number
MX340446B
MX340446B MX2013014640A MX2013014640A MX340446B MX 340446 B MX340446 B MX 340446B MX 2013014640 A MX2013014640 A MX 2013014640A MX 2013014640 A MX2013014640 A MX 2013014640A MX 340446 B MX340446 B MX 340446B
Authority
MX
Mexico
Prior art keywords
methods
staphylococcus aureus
treating
associated conditions
aureus infections
Prior art date
Application number
MX2013014640A
Other languages
English (en)
Other versions
MX2013014640A (es
Inventor
J Torres Victor
Alonzo Francis
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Publication of MX2013014640A publication Critical patent/MX2013014640A/es
Publication of MX340446B publication Critical patent/MX340446B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)

Abstract

La presente invención se refiere a métodos y composiciones para la prevención y el tratamiento de Stahylococcus aureus en un sujeto. Las composiciones terapéuticas de la presente invención comprenden proteínas o polipéptidos de leucocidina E y/o D y anticuerpos anti-leucocidina E y/o D. La invención se refiere además a métodos para identificar inhibidores de citotoxicidad de LuKe/D e inhibidores de unión de LuKe/D a leucocitos.
MX2013014640A 2011-06-19 2012-06-19 Metodos para tratar y prevenir infecciones por estafilococo dorado y condiciones asociadas. MX340446B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161498596P 2011-06-19 2011-06-19
PCT/US2012/043179 WO2012177658A2 (en) 2011-06-19 2012-06-19 Methods of treating and preventing staphylococcus aureus infections and associated conditions

Publications (2)

Publication Number Publication Date
MX2013014640A MX2013014640A (es) 2014-05-14
MX340446B true MX340446B (es) 2016-07-08

Family

ID=47423177

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013014640A MX340446B (es) 2011-06-19 2012-06-19 Metodos para tratar y prevenir infecciones por estafilococo dorado y condiciones asociadas.
MX2016004832A MX357938B (es) 2011-06-19 2012-06-19 Metodos para tratar y prevenir infecciones por staphylococcus aureus y afecciones asociadas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2016004832A MX357938B (es) 2011-06-19 2012-06-19 Metodos para tratar y prevenir infecciones por staphylococcus aureus y afecciones asociadas.

Country Status (20)

Country Link
US (7) US9091689B2 (es)
EP (3) EP3777885A1 (es)
JP (4) JP6170913B2 (es)
KR (1) KR102050267B1 (es)
CN (3) CN104474531A (es)
AU (1) AU2012273123C1 (es)
BR (2) BR122020000047B1 (es)
CA (1) CA2839554C (es)
CL (2) CL2013003650A1 (es)
DK (1) DK3403669T3 (es)
ES (2) ES2812181T3 (es)
HR (1) HRP20201265T1 (es)
HU (1) HUE051832T2 (es)
IL (2) IL229922B (es)
LT (1) LT3403669T (es)
MX (2) MX340446B (es)
NZ (1) NZ764564A (es)
RU (1) RU2635462C2 (es)
SI (1) SI3403669T1 (es)
WO (1) WO2012177658A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3777885A1 (en) * 2011-06-19 2021-02-17 New York University Methods of treating and preventing staphylococcus aureus infections and associated conditions
AU2013257161B2 (en) 2012-05-02 2017-11-09 New York University Methods of treating and preventing Staphylococcus aureus infections and associated conditions
EP3441474B1 (en) * 2013-06-18 2020-07-22 New York University Pharmaceutical compositions containing a mutated leukocidin e
CN105873946A (zh) * 2013-10-17 2016-08-17 阿尔萨尼斯生物科学有限责任公司 交叉反应性金黄色葡萄球菌抗体序列
MX2016007533A (es) * 2013-12-09 2016-12-14 Univ New York Composiciones y metodos para el suministro fagocitico de agentes anti-estafilococicos.
WO2015144691A1 (en) * 2014-03-26 2015-10-01 Glaxosmithkline Biologicals Sa Compositions for immunising against staphylococcus aureus
US20180017559A1 (en) * 2014-08-12 2018-01-18 Arsanis Biosciences Gmbh Predicting s. aureus disease
JP2018513168A (ja) * 2015-04-17 2018-05-24 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 抗スタフィロコッカス・アウレウス抗体組み合わせ製剤
EP3302532A4 (en) 2015-06-05 2019-01-09 New York University COMPOSITIONS AND METHODS RELATED TO ANTISTAPHYLOCOCCAL BIOLOGICAL AGENTS
CN105641689A (zh) * 2016-01-21 2016-06-08 浙江海隆生物科技有限公司 一种奶牛金黄色葡萄球菌β-溶血素亚单位疫苗的制备方法及应用
US11104724B2 (en) 2016-05-23 2021-08-31 New York University Compositions and methods for antibodies targeting staphylococcal leukotoxins
SG10201912431XA (en) 2016-10-21 2020-02-27 Socpra Sciences Et Genie Sec Vaccine constructs and uses thereof against staphylococcus infections
US20200057075A1 (en) * 2017-02-20 2020-02-20 The Regents Of The University Of California Serologic assay for silent brain ischemia
CN107224575B (zh) * 2017-03-06 2018-11-09 浙江海隆生物科技有限公司 奶牛金黄色葡萄球菌乳房炎亚单位疫苗的组合物及其制备方法和应用
CN106749652A (zh) * 2017-03-14 2017-05-31 天津喜诺生物医药有限公司 一种金黄色葡萄球菌肽聚糖的多克隆抗体
CN112672788A (zh) 2018-07-24 2021-04-16 免疫医疗有限责任公司 抗金黄色葡萄球菌凝集因子a(clfa)的抗体
CA3168643A1 (en) * 2019-02-28 2020-09-03 Dandi Bioscience Inc. Polypeptide having antibacterial activity, composition for preventing or treating sepsis comprising same, and antibacterial composition
CN111423516B (zh) * 2020-04-01 2022-02-11 广州佰斯伦医疗器械有限公司 一种蛋白及其在创口修复及抑菌中的应用
CN111398194B (zh) * 2020-04-10 2020-11-03 上海华茂药业有限公司 一种用于测定艾考糊精中肽聚糖的方法
CN112851770B (zh) * 2021-02-05 2022-10-04 中国人民解放军陆军军医大学 一种用于诊断或防治金黄色葡萄球菌感染的α溶血素抗原表位肽及其应用
CN114317787A (zh) * 2021-12-29 2022-04-12 成都大学 吸附磁珠及其试剂盒和用途以及检测金黄色葡萄球菌的方法
CN115991766A (zh) * 2023-03-13 2023-04-21 广州美健生物技术有限公司 一种细菌抗原检测试剂盒及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1121135E (pt) 1998-09-14 2009-03-05 Nabi Biopharmaceuticals Composições de b-glucanos e de imunoglobulinas específicas
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
WO2002077183A2 (en) 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
US20030171563A1 (en) 2001-05-18 2003-09-11 Mcnamara Peter J. Regulators of bacterial virulence factor expression
EP1593680A4 (en) 2003-02-07 2008-05-07 Takeda Pharmaceutical PYRIDINE DERIVATIVES WITH CONDENSED RING, PROCESS FOR THEIR PREPARATION AND USE
IL157398A0 (en) 2003-08-14 2004-02-19 Hadasit Med Res Service Pharmaceutical compositions comprising ccr5 antagonists
US7622125B2 (en) 2004-05-05 2009-11-24 Novartis Vaccines And Diagnostics, Inc. Polycistronic HIV vector constructs
ES2472441T3 (es) 2004-09-22 2014-07-01 Glaxosmithkline Biologicals S.A. Composición inmunog�nica para uso en vacunación contra estafilococos
WO2007062150A2 (en) 2005-11-25 2007-05-31 University Of Medicine And Dentistry Of New Jersey Leukotoxin compositions and therapeutic methods
WO2011047011A2 (en) 2009-10-13 2011-04-21 University Of Medicine And Dentistry Of New Jersey Treatment and diagnosis of inflammatory disorders
US20110143992A1 (en) 2006-02-13 2011-06-16 Dennis Taub Methods and Compositions Related to GHS-R Antagonists
BRPI0712843A2 (pt) 2006-06-12 2012-07-31 Pfizer Prod Inc antagonista de ccr5 e seus usos
MX2008015814A (es) * 2006-06-12 2009-01-12 Nabi Biopharmaceuticals Uso de alfa-toxina para tratar y prevenir infecciones por staphylococcus.
JP2008013447A (ja) * 2006-07-03 2008-01-24 Juntendo 毒素検出方法
EP2120928A2 (en) 2007-02-15 2009-11-25 Pfizer Limited Pharmaceutical compositions and methods for ccr5 antagonists
US8563513B2 (en) 2009-03-27 2013-10-22 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
MX363222B (es) * 2009-04-14 2019-03-15 Novartis Ag Composiciones para inmunizacion contra staphylococcus aureus.
US8409584B2 (en) 2009-05-05 2013-04-02 New York University Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
PL3444268T3 (pl) * 2010-05-05 2022-04-19 New York University Leukocydyny staphylococcus aureus, kompozycje terapeutyczne i ich zastosowania
EP3777885A1 (en) * 2011-06-19 2021-02-17 New York University Methods of treating and preventing staphylococcus aureus infections and associated conditions
US8846609B2 (en) * 2011-06-19 2014-09-30 New York University Leukotoxin E/D as a new anti-inflammatory agent and microbicide

Also Published As

Publication number Publication date
EP2720714B1 (en) 2018-07-18
WO2012177658A2 (en) 2012-12-27
EP3403669A1 (en) 2018-11-21
US20210340228A1 (en) 2021-11-04
EP3403669B1 (en) 2020-07-15
BR112013032774A2 (pt) 2017-01-31
JP6758363B2 (ja) 2020-09-23
RU2635462C2 (ru) 2017-11-13
WO2012177658A3 (en) 2013-02-21
BR112013032774B1 (pt) 2020-05-05
IL229922B (en) 2018-05-31
JP2017214397A (ja) 2017-12-07
JP7129451B2 (ja) 2022-09-01
HRP20201265T1 (hr) 2021-02-19
CA2839554C (en) 2023-09-26
MX2013014640A (es) 2014-05-14
IL258886A (en) 2018-06-28
RU2014101488A (ru) 2015-07-27
CL2019002056A1 (es) 2019-11-29
US20130017203A1 (en) 2013-01-17
LT3403669T (lt) 2020-10-12
WO2012177658A8 (en) 2014-02-20
US10669329B2 (en) 2020-06-02
ES2812181T3 (es) 2021-03-16
CA2839554A1 (en) 2012-12-27
US9783597B2 (en) 2017-10-10
MX357938B (es) 2018-07-31
AU2012273123A1 (en) 2014-01-16
US20180057571A1 (en) 2018-03-01
JP6452765B2 (ja) 2019-01-16
NZ619938A (en) 2016-03-31
SI3403669T1 (sl) 2020-11-30
US10202440B2 (en) 2019-02-12
CN103717234A (zh) 2014-04-09
CN104474531A (zh) 2015-04-01
JP2014520149A (ja) 2014-08-21
ES2684088T3 (es) 2018-10-01
US9481723B2 (en) 2016-11-01
HUE051832T2 (hu) 2021-03-29
US9091689B2 (en) 2015-07-28
BR122020000047B1 (pt) 2021-04-13
US20150274814A1 (en) 2015-10-01
JP2019034976A (ja) 2019-03-07
JP6170913B2 (ja) 2017-07-26
NZ764564A (en) 2022-10-28
US20190135900A1 (en) 2019-05-09
US11078258B2 (en) 2021-08-03
EP2720714A4 (en) 2015-01-14
JP2020193225A (ja) 2020-12-03
AU2012273123C1 (en) 2018-08-09
AU2012273123B2 (en) 2018-01-04
EP3777885A1 (en) 2021-02-17
US20170008953A1 (en) 2017-01-12
CN109893644A (zh) 2019-06-18
EP2720714A2 (en) 2014-04-23
NZ730359A (en) 2020-05-29
KR20140039294A (ko) 2014-04-01
KR102050267B1 (ko) 2019-11-29
CL2013003650A1 (es) 2014-09-26
NZ710439A (en) 2017-04-28
DK3403669T3 (da) 2020-08-24
US20200392211A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
MX2013014640A (es) Metodos para tratar y prevenir infecciones por estafilococo dorado y condiciones asociadas.
PH12018501429A1 (en) Compositions and methods for treating and preventing staphylococcus aureus infections
WO2014052836A3 (en) Methods and compositions for treating infection
HK1207002A1 (en) Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections
MY173518A (en) Antimicrobial compounds and methods of making and using the same
EP3268010A4 (en) Compositions and methods for treating bacterial infection
EP3626241A4 (en) N-BENZOLSULFONYLBENZAMIDE COMPOUND FOR INHIBITING BCL-2 PROTEIN AND COMPOSITION AND USE THEREOF
WO2017075188A3 (en) Methods of using anti-alpha toxin antibody
MX2015008486A (es) Composiciones y metodos para tratar infecciones bacterianas.
EP2844258A4 (en) METHOD AND COMPOSITIONS FOR TREATING BACTERIAL INFECTIONS
HK1210163A1 (en) Compositions and methods for treating or preventing pneumovirus infection and associated diseases
PH12014502677A1 (en) Binders
EP2982378A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF SEPSIS OR SEPTIC SHOCK WITH ADK PROTEIN AS AN ACTIVE SUBSTANCE
IN2014DN08610A (es)
PH12015500518A1 (en) Tricyclic tetrahydroquinoline antibacterial agents
HK1192904A1 (zh) 用於癒合或治療傷口的分子靶標
EP2593134A4 (en) PROTECTIVE VACCINE BASED ON STAPHYLOCOCCUS AUREUS SA2412 PROTEIN
GB201114923D0 (en) Immunogenic proteins and compositions
IL240241B (en) Antibodies directed to bacillus anthracis protective antigen
AU2015900546A0 (en) Agents and methods for inhibiting virus infection
GB201104082D0 (en) Molecular targets for healing or treating wounds
GB201103962D0 (en) Molecular targets for healing or treating wounds

Legal Events

Date Code Title Description
FG Grant or registration